Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug Biktarvy in a late-stage study involving previously untreated adult ...

Gilead Sciences' triple-threat Biktarvy is already a standout in the HIV treatment space—and it’s the company's top seller, to boot. Now, Gilead is trumpeting data that could pave the way to millions ...

Merck (MRK) announced on Wednesday that its single-tablet antiviral regimen, doravirine and islatravir for adults with HIV, was found to be non-inferior to Gilead’s (GILD) once-daily HIV pill Biktarvy ...

Gilead Sciences (GILD) just got a confidence boost from Wall Street, with Truist initiating coverage at Buy and Mizuho ...

– Perinatal Guidelines Recognize Biktarvy as Alternative Regimen for Use During Pregnancy and for Those Trying to Conceive – The updated label now includes additional data from Study 5310, a Phase 1b, ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read more on GILD stock here.

Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval molecule as a new anchor treatment for the infectious disease. Integrase strand ...

To make Cabenuva the standard treatment option for HIV, Johnson & Johnson and GSK-owned ViiV Healthcare must first dethrone Gilead Sciences’ once-daily stalwart Biktarvy. Now, the partners have a ...

(RTTNews) - The U.S. Food and Drug Administration approved a new, expanded indication for Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat people ...

Gilead Sciences has received permission from the Food and Drug Administration for an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy (bictegravir 50 ...